Purchase Order HT001424P0164
Award Date
7/8/24
Potential Completion Date
6/18/29
Potential Value
$369K
Federal Agency
Defense Health Agency
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20889, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $214,560.00, is for the delivery of INT2540B DROP SHIPMENT FOR PLATELET PROCESSING. This contract has no set-aside designation. Cerus Corporation is the prime contractor and there are no major subcontractors identified. The contract supports medical...
The Defense Health Agency awarded Cerus Corporation, a biomedical products company, a firm-fixed-price purchase order contract worth $190,080.00 for the supply of INTERCEPT Platelet Processing Sets and INTERCEPT Platelet Processing Sets with Dual Storage Containers. The contract is a sole-source award due to the proprietary nature of Cerus Corporation's INTERCEPT Blood System technology, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. This pathogen...
This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
This federal contract award to Cerus Corporation, a biomedical products company, is for the delivery of INTERCEPT Platelet Processing Kits. The award, valued at $232,128.00, was made by the Defense Health Agency (DHA), a component of the Department of Defense. The contract has a period of performance ending on September 30, 2027. Cerus Corporation's INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, plays a crucial role in reducing...
The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
This contract was awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract is for the procurement of Cerus Intercept Platelet Pathogen Reduction Sets, which use a chemical agent and ultraviolet light to inactivate pathogens in blood products, primarily platelets and plasma. The contract is a firm-fixed-price purchase order with a ceiling value of $258,240.00 and a period...
This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
This is a $282,450,108.67 federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation. The contract is for the development and implementation of Cerus's proprietary pathogen reduction technology (PRT) known as the INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, helping to reduce the risk of transfusion-transmitted infections. The...
The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...